Literature DB >> 22217997

3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects.

A Antonelli1, P Fallahi, S M Ferrari, A Di Domenicantonio, M Moreno, A Lanni, F Goglia.   

Abstract

Recently, it was demonstrated that 3,5-diiodo-L-thyronine (T2) stimulates the resting metabolic rate (RMR), and reduces body-weight gain of rats receiving a high-fat diet. The aim of this study is to examine the effects of chronic T2 administration on basal metabolic rate and body weight in humans. Two euthyroid subjects volunteered to undergo T2 administration. Body weight, body mass index, blood pressure, heart rate, electrocardiogram, thyroid and liver ultrasonography, glycemia, total cholesterol, triglycerides, free T3 (FT3), free T4 (FT4), T2, thyroid stimulating hormone (TSH) and RMR were evaluated at baseline and at the end of treatment. RMR increased significantly in each subject. After continuing the T2 treatment for a further 3 weeks (at 300 mcg/day), body weight was reduced significantly (p<0.05) (about 4 percent), while the serum levels of FT3, FT4 and TSH, were unchanged. No side effects were observed at the cardiac level in either subject. No significant change was observed in the same subjects taking placebo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22217997

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  29 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 2.  Novel thyroid hormones.

Authors:  Riccardo Zucchi; Grazia Rutigliano; Federica Saponaro
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

Review 3.  Thyroid hormone analogues and derivatives: Actions in fatty liver.

Authors:  Maria Coppola; Daniela Glinni; Maria Moreno; Federica Cioffi; Elena Silvestri; Fernando Goglia
Journal:  World J Hepatol       Date:  2014-03-27

Review 4.  Lipid lowering effects of iodothyronines: In vivo and in vitro studies on rat liver.

Authors:  Laura Vergani
Journal:  World J Hepatol       Date:  2014-04-27

5.  Translating pharmacological findings from hypothyroid rodents to euthyroid humans: is there a functional role of endogenous 3,5-T2?

Authors:  Maik Pietzner; Ina Lehmphul; Nele Friedrich; Claudia Schurmann; Till Ittermann; Marcus Dörr; Matthias Nauck; René Laqua; Uwe Völker; Georg Brabant; Henry Völzke; Josef Köhrle; Georg Homuth; Henri Wallaschofski
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

6.  Acute administration of 3,5-diiodo-L-thyronine to hypothyroid rats stimulates bioenergetic parameters in liver mitochondria.

Authors:  Alessandro Cavallo; Federica Taurino; Fabrizio Damiano; Luisa Siculella; Anna Maria Sardanelli; Antonio Gnoni
Journal:  J Bioenerg Biomembr       Date:  2016-11-17       Impact factor: 2.945

Review 7.  Triiodothyronine and breast cancer.

Authors:  Maria Teresa De Sibio; Miriane de Oliveira; Fernanda Cristina Fontes Moretto; Regiane Marques Castro Olimpio; Sandro José Conde; Aline Carbonera Luvizon; Célia Regina Nogueira
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 8.  Thyroid hormone metabolites and analogues.

Authors:  Rosalba Senese; Federica Cioffi; Giuseppe Petito; Fernando Goglia; Antonia Lanni
Journal:  Endocrine       Date:  2019-07-29       Impact factor: 3.633

Review 9.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  3,3'-Diiodothyronine concentrations in hospitalized or thyroidectomized patients: results from a pilot study.

Authors:  Jacqueline Jonklaas; Anpalakan Sathasivam; Hong Wang; David Finigan; Offie P Soldin; Kenneth D Burman; Steven J Soldin
Journal:  Endocr Pract       Date:  2014-08       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.